RTTNews

Takeda's Zasocitinib NDA Gets FDA Priority Review For Plaque Psoriasis; PDUFA Date Set For Q1' 27

Johnson & Johnson's Icotyde (icotrokinra), an oral IL-23 receptor antagonist, was approved by the FDA in 2026 for the treatment of moderate-to-severe plaque psoriasis. TAK closed Friday's trade at $18 ...
EuropaWire

Takeda’s Zasocitinib Receives FDA Priority Review for Moderate-to-Severe Plaque Psoriasis Following Positive Phase 3 Results in Nearly 3,000 Patients

Armstrong AW, et al. Zasocitinib, a once-daily oral TYK2 inhibitor, demonstrates efficacy at high impact sites in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 ...
Agence France-Presse

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment ...

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of ...
nytimes.com

President Trump’s Approval Rating: Latest Polls

This is a daily average of polls conducted by dozens of different organizations since Inauguration Day. See the latest polls. About this data Note: Individual poll results are shown as circles. Polls ...